Dipexium prices upsized IPO at $12, the low end of the range

By
A A A

Dipexium Pharmaceuticals, a late-stage biotech developing a topical antibiotic for diabetic foot ulcer infections, raised $33 million by offering 2.8 million shares (upsized from 2.3 million) at $12, the low end of the $12 to $14 range. Dipexium Pharmaceuticals will list on the NASDAQ under the symbol DPRX. Oppenheimer & Co. acted as sole bookrunner on the deal.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks: DPRX

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Stocks

Referenced

100%

Most Active by Volume

61,354,178
  • $10.59 ▲ 13.26%
57,732,182
  • $16.27 ▲ 1.12%
51,991,548
  • $103.30 ▲ 0.78%
48,129,834
  • $20.65 ▲ 5.52%
41,623,916
  • $12.63 ▲ 8.13%
34,295,241
  • $76.68 ▲ 2.49%
31,519,079
  • $34.57 ▼ 1.00%
28,847,879
  • $3.64 ▲ 0.28%
As of 9/2/2014, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com